XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B XOMAO 深 沪
等待开盘 05-19 09:30:00 美东时间
25.35
+0.035
+0.14%
华盛通- 最 高25.37
- 今 开25.34
- 成交量 4068股
- 最 低 25.25
- 昨 收 25.315
- 总市值 4462.87万
- 52周最高 26.40
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 23.0628
- 委 比 -45.21%
- 总股本 176.05万
- 历史最高 26.40
- 量 比 1.14
- 振 幅 0.47%
- 历史最低 13.5463
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
An announcement from XOMA Royalty Corporation ( ($XOMA) ) is now available. On ...
05-18 22:08
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-27 23:24
Suja Life launches IPO roadshow, targets $21–$24 per share
Suja Life (SUJA) on Monday said it has begun the roadshow for its initial public offering of 8,888,889 Class A shares, with a price range of $21 to $24 per share. Of the total shares, 8,688,170 are be...
04-27 19:40
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to acquire XOMA Royalty for $39 per share, totaling $739 million. The deal adds over 120 assets, including 7 commercial products and nearly doubles Ligand's Phase 2 and 3 pipeline. Ligand expects the transaction to be immediately accretive to EPS, raising 2026 adjusted EPS guidance to $8.50-$9.50 and adding $1.50 per share in 2027. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and stockhol...
04-27 11:00
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. reported updates on its lead candidate MICVO, including completion of target enrollment in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first quarter of 2026. The company also announced updated data expected in mid-2026, which will include patients treated with modified weight-based dosing. Additionally, Pyxis Oncology shared financial results for 2025, includin...
03-23 11:00
XOMA Royalty Corporation (XOMA) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on XOMA Royalt...
03-20 18:36
